粉样和可能在认知不受损的风险样本中对语义和情节性记忆产生适度的实践效应
Kristin Basche1, Madeline Hale2, Erin Jonaitis1,3,4
1Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Brain communications
|October 31, 2025
概括
阿尔茨海默病的研究表明,粉样蛋白和蛋白生物标志物影响认知实践效应,特别是在语言任务中. 年龄可能会影响这些关联,需要进一步调查相互交织的因素.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 生物标志物研究 生物标志物研究
背景情况:
- 以前的阿尔茨海默病 (AD) 研究将粉样蛋白与实践效应联系起来.
- 研究表明,实践效应与认知测试相关,包括语言测量.
- 语言测量与AD生物标志物相关,这表明存在联系.
研究的目的:
- 调查实践效应如何影响阿尔茨海默病生物标志物组之间的差异.
- 将tau状态纳入检查实践效应和认知表现的模型.
- 探索粉样蛋白和蛋白生物标志物对基于语言的认知任务中的实践效应的影响.
主要方法:
- 利用了来自威斯康星州阿尔茨海默病预防注册研究 (n=442,Aim 3 n=397) 的数据.
- 采用线性混合效应模型和Akaike信息标准 (AIC) 进行模型选择.
- 检查了生物标志物状态 (粉样蛋白,) 与实践相互作用对特定语言措施的影响.
主要成果:
- 实践效应改善了适合所有语言结果的模型.
- 氨基酸状况对逻辑记忆测量 (正名,总分) 的适度实践影响.
- 与粉样蛋白/粉样蛋白阴性 (A-T-) 个体相比,粉样蛋白/粉样蛋白阳性 (A+T+) 个体从实践中获得的益处较小.
结论:
- 粉样蛋白和联合粉样蛋白/粉样蛋白状态影响语言任务的实践效应.
- 年龄可能是观察到的关联的一个混因素.
- 需要进一步的研究来解开阿尔茨海默病中年龄,实践和认知衰退的影响.
更多相关视频
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
4.0K
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.8K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
